Association between high-density lipoprotein cholesterol to apolipoprotein A ratio and diabetic retinopathy: A cross-sectional study.

[1]  E. Castelblanco,et al.  Predictive Value of the Advanced Lipoprotein Profile and Glycated Proteins on Diabetic Retinopathy , 2022, Nutrients.

[2]  K. Venkataraman,et al.  Leveraging knowledge of HDLs major protein ApoA1: Structure, function, mutations, and potential therapeutics. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  P. Gabrielle.  Lipid metabolism and retinal diseases , 2022, Acta ophthalmologica.

[4]  Meidong Zhu,et al.  Plasma Apolipoproteins Predicting the Occurrence and Severity of Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus , 2022, Frontiers in Endocrinology.

[5]  M. Gissler,et al.  Changes in Visual Impairment due to Diabetic Retinopathy During 1980–2019 Based on Nationwide Register Data , 2022, Diabetes care.

[6]  Xue-qin Wang,et al.  Comparisons of the Relationships Between Multiple Lipid Indices and Diabetic Kidney Disease in Patients With Type 2 Diabetes: A Cross-Sectional Study , 2022, Frontiers in Endocrinology.

[7]  Yue Wang,et al.  Associations between the HDL-C/ApoA-I ratio and fasting glucose levels differ by glucose deciles, HDL-C/ApoA-I ratio ranges and sex. , 2022, Diabetes research and clinical practice.

[8]  J. Grauslund.  Diabetic retinopathy screening in the emerging era of artificial intelligence , 2022, Diabetologia.

[9]  G. Liew,et al.  Thirty-Year Time Trends in Diabetic Retinopathy and Macular Edema in Youth With Type 1 Diabetes. , 2022, Diabetes Care.

[10]  Juan Zhou,et al.  HDL-C/apoA-I Ratio Is Associated with the Severity of Coronary Artery Stenosis in Diabetic Patients with Acute Coronary Syndrome , 2021, Disease markers.

[11]  T. Wong,et al.  Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. , 2021, Ophthalmology.

[12]  Xingmin Wang,et al.  Association of apolipoproteins A1 and B with type 2 diabetes and fasting blood glucose: a cross-sectional study , 2021, BMC Endocrine Disorders.

[13]  C. Aguilar-Salinas,et al.  The influence of high-density lipoprotein (HDL) and HDL subfractions on insulin secretion and cholesterol efflux in pancreatic derived β-cells , 2021, Journal of Endocrinological Investigation.

[14]  G. Sesti,et al.  HDL (High-Density Lipoprotein) and ApoA-1 (Apolipoprotein A-1) Potentially Modulate Pancreatic α-Cell Glucagon Secretion , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[15]  A. Esteghamati,et al.  Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas, 9th edition. , 2020, Diabetes Research and Clinical Practice.

[16]  L. Eliasson,et al.  Apolipoprotein A-I primes beta cells to increase glucose stimulated insulin secretion. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[17]  R. Marfella,et al.  High HDL cholesterol: A risk factor for diabetic retinopathy? Findings from NO BLIND study. , 2019, Diabetes research and clinical practice.

[18]  K. Sung,et al.  The HDL cholesterol/apolipoprotein A-I ratio: an indicator of cardiovascular disease , 2017, Current opinion in endocrinology, diabetes, and obesity.

[19]  2. Classification and Diagnosis of Diabetes , 2016, Diabetes Care.

[20]  M. Laakso,et al.  Associations of multiple lipoprotein and apolipoprotein measures with worsening of glycemia and incident type 2 diabetes in 6607 non-diabetic Finnish men. , 2015, Atherosclerosis.

[21]  V. Gebski,et al.  HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes , 2014, Diabetes Care.

[22]  Y. Hwang,et al.  Association of HDL-C and apolipoprotein A-I with the risk of type 2 diabetes in subjects with impaired fasting glucose. , 2014, European journal of endocrinology.

[23]  Samia Mora,et al.  A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. , 2013, Clinical chemistry.

[24]  Walter T Ambrosius,et al.  Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.

[25]  P. Ridker,et al.  Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women , 2010, Diabetes.

[26]  Costantina Manes,et al.  Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy , 2010, Circulation.

[27]  Cristina Hernández,et al.  Apolipoprotein A1 is overexpressed in the retina of diabetic patients. , 2009, American journal of ophthalmology.

[28]  Christina Lindahl,et al.  High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. , 2008, Journal of the American College of Cardiology.

[29]  P. Mitchell,et al.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.

[30]  D. Lackland,et al.  Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. , 2004, Investigative ophthalmology & visual science.

[31]  B. Hoogwerf,et al.  Serum Lipids and Diabetic Retinopathy , 1996, Diabetes Care.

[32]  J. A. Watters,et al.  Screening for Diabetic Retinopathy: The wide-angle retinal camera , 1993, Diabetes Care.